Special Focus on Hospital Acquired Infections and Detection

JAVASCRIPT DISABLED - This site works best with JavaScript enabled.

« Previous article
COVID-19 or Flu? a r...

Next article »
Latest Updates on CO...

9th November 2020 Content supplied by: various sources as indicated

Special Focus on Hospital Acquired Infections and Detection of Resistance

Carbapenamase-Resistant Enterobacterales (CRE) infections were generally low during the peak of the first wave of COVID-19. Fewer patients were attending hospitals for testing during those times, and when restrictions were lifted, CRE positive cases sky-rocketed and caught up with previous years.

We might of put the threat of antimicrobial resistance at the back of our minds during this pandemic, but its everpresent danger is not to be ignored.

When a patient presents with an infection, frontline antibiotics (ABs) will be applied. But due to antimicrobial resistance (AMR), there's an increasing chance those frontline ABs will be ineffective and more sophisticated diagnostics tools are required to identify the pathogen.

With the advent of rapid diagnostics, it is hoped fatalities and patient's time under care will be reduced. The use of MALDI-ToF technology and multiplex RT-PCR to identify pathogens faster requires centralisation of clinical labs into one mega-lab; in order to reduce costs overall.

However, time taken sending samples and receiving results has shown little advantage. Laboratories found a return to simple cost-saving techniques, such as chromogenic agar, antibiotic discs and lateral-flow technology can deliver results in the same time-frame.

In this rapidmicrobiology.com special focus on hospital-acquired infections (HAI) and AMR, suppliers of clinical diagnostics showcase simple and rapid tests for minimum inhibitory concentration (MIC), antibiotic susceptibility testing (AST), AMR surveillance and antimicrobial resistance mechanism detection.

The Winnable Battles: HAIs' and Antimicrobial Stewardship

The CDC classifies HAI’s as “Winnable Battles” and commits surveillance to reduce the incidence of HAI’s and improve patient outcome. The emergence of carbapenem-resistant Enterobacterales (CRE) is an urgent threat, requiring immediate action.
Find Out More

CHROMagar™ Candida Plus, First Chromogenic Medium for C. auris

CHROMagar™ Candida Plus, First Chromogenic Medium for <em>C. auris</em>

CHROMagar™ Candida Plus is a unique medium to differentiate C. auris from other Candida spp. - with 100 % specificity and sensitivity for C. auris strains, it is the perfect tool for investigation of outbreaks. Plus, win an iPad!
Find Out More

Condalab Solutions for Detection of Antibiotic Resistance

Each year, about 3 million people are infected in the US with antibiotic-resistant strains. In Europe, 33,000 people die because of them every year. How important is early diagnosis? Find out what solutions we can offer you here in Condalab.
Find Out More

Rapid Surface Testing for COVID-19: Detect the Virus in 10 Minutes!

Developed by ProGnosis Biotech, the Rapid Surface Ag 2019-nCov detects, in just a few steps, the presence of SARS-CoV-2 on common surfaces. Using a simple & innovative method, the test does not require special equipment and produces real-time results in just 10 mins!
Find Out More

Liofilchem’s Solutions for Antimicrobial Susceptibility Testing

Liofilchem produces MTS™ (MIC Test Strip), antibiotic discs, ready-to-use agar dilution panels, ComASP^® compact broth microdilution panels, rapid NP^® tests and chromogenic media for antimicrobial susceptibility testing and resistance mechanisms detection.
Find Out More

AMR Surveillance with BIOMIC V3: Five Key Advantages

BIOMIC V3 is an open system utilizing digital imaging to automate the reading and CLSI/EUCAST interpretation of AST-ID-QC from various manufacturers. BIOMIC V3 is designed and manufactured by Giles Scientific in California.
Find Out More

Is It Bacterial or Viral? - Triage Assay Tested on COVID-19 Symptomatic Patients

Study results have been released on Lumos Diagnostics' viral and bacterial infection biomarker assay, FebriDx^®to assess its potential to rapidly triage patients with symptomatic respiratory infections during the COVID-19 pandemic. (Not available in US)
Find Out More

Screen and Interpret Thousands of MRSA Plates Daily Through Automated Imaging

LBT Innovations has licensed its AI-powered MRSA plate screening and interpretation software to the largest clinical laboratory group in Germany. The APAS independence system with the MRSA Analysis Module can do thousands of plates per day.
Find Out More

Tags: